◈ Nootpedia
Compact view
Research pass: thorough Supplement · Powder STRONG-CANDIDATE HIGH

L-Tryptophan

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict STRONG-CANDIDATE HIGH

A-tier evidence for sleep onset latency reduction at 1 g+ doses with the proper timing (empty stomach, 30-60 min pre-bed); cheap; clean side effect profile; pharmacologically more relevant than glycine for a late-chronotype migrating earlier (it actually feeds the melatonin pathway, glycine doesn't). Would shift to PRIMARY-PICK if Dylan's bloodwork shows low ferritin/B6/Mg (which would otherwise bottleneck conversion).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    STRONG-CANDIDATE

    Replaces V4 glycine. Better evidence base; better mechanism for melatonin-pathway support during late-chronotype-to-midnight migration. Pairs with existing magnesium glycinate. Daily-safe, no tolerance, cheap. Expected ROI: 15-30 min faster sleep onset + cleaner sleep continuity. Verdict justified.

  • 30-50, executive maintenance
    STRONG-CANDIDATE

    Same logic. If life stress / job-related serotonergic depletion present, response may be more pronounced.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    Aging brings declining 5-HT system function and worse sleep architecture. Tryptophan is reasonable, but melatonin (low-dose) often does more work in this group because pineal output declines with age. Stack tryptophan + melatonin if both deficits present.

  • Anxiety-prone
    STRONG-CANDIDATE

    Serotonin system tone matters for anxiety. Less acute than benzo or buspirone, but daily-safe and stack-friendly. Pairs with theanine (already in V4) and magnesium.

  • High athletic load, tested status
    STRONG-CANDIDATE

    Not WADA-banned. Training drives inflammation and serotonergic depletion (the "central fatigue" hypothesis: rising tryptophan:BCAA ratio during prolonged exercise drives perceived exertion via brain serotonin). Tryptophan supplementation pre-bed supports recovery without exercise-time interference. Some athletes specifically avoid daytime tryptophan because of central-fatigue concerns; pre-bed dose sidesteps this.

  • Sleep-disordered
    PRIMARY-PICK

    candidate. Strongest evidence base for mild-to-moderate insomnia is in this profile. Real chronic insomnia might still need orexin antagonists (daridorexant) or CBT-I, but tryptophan is the right first-line supplement and worth a 4-8 week trial before escalating.

  • Recovery-focused (post-injury, post-illness)
    STRONG-CANDIDATE

    Inflammation will partially divert via kynurenine, but support for sleep onset still useful. Address inflammation in parallel (omega-3, curcumin, hs-CRP monitoring).

  • Strength/anabolic-focused
    OPTIONAL-ADD

    Not directly anabolic, but sleep quality is a major determinant of recovery and testosterone. Worth adding for sleep, not for direct anabolic effect.

▸ Subjective experience (deep)

Per user reports and the small body of subjective-rating data:

  • Onset: 30-60 min after dose on empty stomach. Some report a mild "warmth" or relaxation by 45-60 min.
  • Peak: ~60-120 min post-dose. Most pronounced effect: gentle drowsiness, not knockout. Body relaxes. Not the "GABAergic mush" feel of phenibut/Z-drugs — much cleaner.
  • Sleep: Falling asleep is easier; many report fewer middle-of-night awakenings.
  • Dreams: Vivid dreams in maybe 30-40% of users, especially early in protocol. Some find this fascinating, some find it annoying. Often fades with continued use.
  • Morning: No grogginess at 1 g doses. This is one of tryptophan's best features vs antihistamines (diphenhydramine) or Z-drugs.
  • Mood: Subtle mood lift over 1-2 weeks of consistent dosing in some users; not a serotonergic "rush" — more a baseline smoothing.

Variability: 5-HTTLPR S/S carriers respond more strongly (van Dalfsen 2019). High-inflammation states (CRP elevated, sleep-deprived, sick, overtraining) likely blunt response via the kynurenine shunt. Low B6 / low Mg / low Fe also blunt response (TPH cofactor deficiency).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal/none at supplement doses. Tryptophan is restoring substrate, not pushing receptors. No reported pharmacological tolerance.
  • Recommended cycle: Daily, indefinitely. No cycle needed. This is one of tryptophan's strongest features for daily-driver sleep stack.
  • Reset protocol: N/A — no tolerance to reset. If subjective effect dims, suspect (1) increased inflammation/IDO activity, (2) cofactor depletion (B6, Mg, Fe), or (3) the placebo phase wearing off.
▸ Stacking deep dive

Synergistic with

  • magnesium-glycinate — already in V4 at 400 mg elemental. Mg is a TPH cofactor and a calming GABAergic adjunct. Strong pairing.
  • vitamin-b6 (P5P) — direct AAAD cofactor (5-HTP → serotonin step). Add 25-50 mg P5P with tryptophan if response suboptimal. Not currently in V4.
  • melatonin (low-dose, 0.3-0.5 mg phase-shift dose) — feeds different points of the same pathway; tryptophan = substrate, melatonin = downstream phase-shift signal. Stacks cleanly.
  • l-theanine (200 mg, already in V4) — different mechanism (GABA/glutamate) but additive on subjective relaxation. Fine to co-administer pre-bed.
  • glycine (technically) — see "Replaces" below. Glycine has a real but small effect (lowers core body temp, NMDA modulation) that doesn't conflict with tryptophan. Could co-administer, but the V5 plan correctly drops it because it adds cost/pill burden for marginal effect, and the evidence base for glycine sleep is weaker (mostly Ajinomoto-funded small trials).
  • carbohydrate (small, ~15-20 g) — insulin-mediated LNAA shunt. Strongest evidence-backed timing trick.
  • agomelatine (Rx melatonin agonist + 5-HT2C antagonist) — would stack mechanistically but Dylan is not on it; flagged for completeness.

Replaces

  • glycine (V4: 3 g pre-bed) — explicit V5 swap. Glycine: F-grade evidence per Dylan's prior research (small Ajinomoto-funded trials, no independent replication, mechanism for sleep is plausible-but-thin). Tryptophan: A-tier evidence + mechanistically more relevant for melatonin pathway in a late-chronotype trying to phase-advance. Tryptophan wins on both evidence and mechanism for Dylan's specific use case. Both could be co-administered (no antagonism), but pill burden/cost optimization argues for one or the other.

Avoid stacking with

  • 5-htp — redundant; adds 5-HTP without the regulatory benefit of tryptophan's TPH gating. Pick one. Tryptophan is preferred for the regulatory/quality-control reason discussed in Mechanism.
  • High-protein meals or protein shakes within 2 hours of dose — LNAA competition kills brain delivery. Time the dose accordingly. (Bedtime dose is naturally far from training-day protein.)
  • MAOIs (selegiline at low MAO-B selective doses likely fine, but selegiline ≥10 mg/day loses selectivity; phenelzine/tranylcypromine are real risk). Dylan's V5 includes optional selegiline 1-2.5 mg/day — at this dose, selectivity for MAO-B is preserved and serotonin syndrome risk with tryptophan is low. Above 5 mg/day selegiline, treat as MAOI and reduce or skip tryptophan.
  • Tramadol, triptans, dextromethorphan in cough syrups — modest serotonergic load. Not fatal at supplement tryptophan doses but worth pausing tryptophan during a tramadol course.

Neutral / safe co-administration

  • All other V4 stack items (DHA, magtein, citicoline, NAC, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C).
  • Modafinil (V5 plan) — different mechanism, AM dosing, no overlap with PM tryptophan. Safe.
  • Bromantane, Adamax/Semax, ALCAR — all AM, no overlap.
  • Creatine — no interaction.
▸ Drug interactions deep dive
Drug class Concern level Notes
MAOIs (phenelzine, tranylcypromine, isocarboxazid) HIGH — avoid Real serotonin syndrome risk.
Selegiline ≤5 mg/day LOW MAO-B selective at this dose; tryptophan typically OK. Above 5 mg, treat as full MAOI.
SSRIs (fluoxetine, sertraline, escitalopram, etc.) LOW-MODERATE Theoretical serotonin syndrome risk. Clinical use does combine (older lit, e.g., fluoxetine + tryptophan for refractory depression, "the California rocket fuel" of older psych practice). Real-world reports of serotonin syndrome with this combo are rare. Worth flagging but not contraindicated.
SNRIs (venlafaxine, duloxetine) LOW-MODERATE Same logic as SSRIs.
Tramadol MODERATE Tramadol has SNRI activity. Pause tryptophan during course.
Triptans (sumatriptan etc.) LOW Modest concern for migraine sufferers; PRN use of triptan + daily tryptophan is generally tolerated.
Dextromethorphan (high doses) LOW Cough-syrup doses fine; recreational doses + tryptophan = bad.
Linezolid (antibiotic) HIGH Has MAOI activity. Avoid tryptophan during course.
Lithium LOW Sometimes co-prescribed historically (lithium augments serotonergic effect). No specific contraindication.
Bupropion (V5 optional) LOW Bupropion is NDRI, minimal serotonergic load. No real risk.

CYP enzymes: Tryptophan is not a CYP substrate or inhibitor in any clinically relevant way. No CYP-mediated interactions.

Contraceptives: No interaction.

▸ Pharmacogenomics

Variants Dylan should check from 23andMe (June 2026):

  • 5-HTTLPR (SLC6A4 promoter variant) — short (S) allele carriers have reduced serotonin transporter expression → higher baseline extracellular 5-HT but lower 5-HT system efficiency. S-allele carriers respond more strongly to tryptophan supplementation (van Dalfsen 2019). 23andMe doesn't directly genotype 5-HTTLPR (it's an indel, not a SNP), but related SNPs (rs25531, rs4795541) give partial info. Promethease/SelfDecode interpret raw data more thoroughly.
  • TPH2 SNPs (rs4570625 G-703T promoter; rs4290270; rs7305115) — affect brain serotonin synthesis rate. Some variants associated with depression/suicidality risk. T carriers of rs4570625 may have lower TPH2 activity → more substrate-limited → potentially better tryptophan response (untested directly).
  • TPH1 SNPs (A218C, A779C) — peripheral pineal/gut TPH. Less neuropsychiatrically relevant; more relevant to peripheral 5-HT (gut, platelet).
  • MAO-A VNTR (low-activity vs high-activity allele) — high-activity = faster serotonin breakdown. Low-activity = slower, possibly lower tryptophan need. Famous "warrior gene" variant — Dylan should check this for general behavioral/aggression context, not just tryptophan dosing.
  • IDO1 / TDO2 SNPs — affect kynurenine flux. Not commonly reported by 23andMe; needs raw-data analysis.
  • MTHFR (C677T, A1298C) — affects methylation, indirectly affects BH4 (TPH cofactor). C677T homozygous T/T = reduced BH4 regeneration → potentially blunted serotonin synthesis. Very common variant. If positive, methylfolate (5-MTHF) and methyl-B12 supplementation may help.

Practical action after 23andMe results land (~June 5-15): If S/S 5-HTTLPR or T/T MTHFR or low-activity MAO-A → tryptophan response should be above average. If L/L 5-HTTLPR → response may be subtle; trial period is informative.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC Nootropics Depot L-Tryptophan 500 mg caps ~$15-20 / 60 caps (~1 mo at 1 g/day) HIGH Third-party tested, CoA available. Top pick for Dylan.
OTC Doublewood L-Tryptophan 500 mg caps ~$15-18 / 60 caps HIGH CoA available; reputable mid-tier.
OTC NOW Foods L-Tryptophan 500 mg caps ~$13-15 / 60 caps (iHerb) HIGH Already in iHerb supply chain Dylan uses; convenient.
OTC Bulk Supplements L-Tryptophan powder ~$10-12 / 100 g (~3 mo) MED-HIGH Cheapest, but requires scoop measurement; CoA published per batch. Decent for cost-optimizers.
OTC Swanson TryptoPure-grade caps ~$15 / 90 caps HIGH TryptoPure is Ajinomoto's pharmaceutical-grade fermentation product — gold standard purity.
Avoid Unknown brands without CoA — LOW EMS legacy means manufacturing standards still matter.

Recommended for Dylan: NOW Foods L-Tryptophan 500 mg, 2 caps pre-bed, via iHerb. Reasons: (1) already in Dylan's iHerb cart workflow, (2) NOW publishes CoAs and uses TryptoPure, (3) ~$13-15/mo fits the V4 budget.

V5 swap math: Drop NOW Foods Glycine 3 caps/day ($8-10/mo) → add NOW Foods Tryptophan 2 caps/day ($13-15/mo). Net: +$3-5/mo to V4 monthly cost. Negligible.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Plasma tryptophan + kynurenine:tryptophan ratio if available (specialty panels — not standard CMP).
  • hs-CRP — inflammation marker; predicts kynurenine-shunt magnitude.
  • B6 (PLP), RBC magnesium, ferritin — TPH/AAAD cofactors.
  • 25(OH)D — Dylan already tracking.
  • Subjective sleep diary baseline — sleep onset latency, WASO, total sleep time, morning grogginess (1-10 scale) for 7-14 days pre-trial. Most actionable for Dylan since labs come in June.

During use

  • Sleep diary metrics weekly for first month, monthly after.
  • Subjective mood (1-10) weekly.
  • If response disappointing at 4 weeks: re-check hs-CRP, B6, Mg, ferritin.

Post-cycle (if ever cycled)

  • N/A — daily-safe, no cycling needed.
▸ Controversies / open debates Live debate

  1. Sleep onset latency vs WASO — which does tryptophan really improve? Older PSG studies (Hartmann era, 1980s) consistently showed sleep onset latency reduction. Modern meta-analysis (Sutanto 2022) shows clearer signal for WASO than SOL. Possible explanations: (a) heterogeneous methodology, (b) modern sleepers have different baseline profiles, (c) the SOL effect is real but smaller than originally reported and gets washed out in pooled analysis. Best read: at 1 g+ doses, expect both — but WASO improvement is more reliable.

  2. Is the carb co-ingestion trick actually necessary? Mechanistically defensible, but the bedtime dose is naturally far from a high-protein meal anyway, so the practical magnitude of the benefit on top of "empty stomach" timing is probably small. Don't overthink it.

  3. EMS lingering anxiety vs evidence. Some functional medicine practitioners still recommend avoiding tryptophan because of EMS history. This is overcautious given current QC standards. The Showa Denko event was a single-manufacturer process failure, not a tryptophan-the-molecule problem. Stick to CoA-publishing brands.

  4. Tryptophan vs 5-HTP — the eternal serotonin-precursor debate. Pro-5-HTP camp argues bypassing TPH gives more reliable serotonin elevation. Pro-tryptophan camp (where this verdict lands) argues regulatory bottleneck = feature, not bug; preserves physiological control; avoids 5-HTP's downstream dopamine depletion concern. Tryptophan wins for daily-driver maintenance use; 5-HTP only makes sense if a clinician is using it tactically.

  5. The glycine-vs-tryptophan switch. Glycine has its own mechanism (lowers core body temp, glycine receptor activity, NMDA-coreceptor effects). Some users find glycine works for them and tryptophan doesn't. Both are individually defensible; the V5 swap is justified for Dylan because (a) tryptophan has stronger evidence, (b) tryptophan addresses the late-chronotype melatonin-pathway angle that glycine doesn't, (c) one less pill/cost item. If Dylan trials tryptophan and finds it inferior to glycine over 4-8 weeks, swapping back is trivial — they're not antagonistic, just redundant for sleep.

  6. Kynurenine pathway concern in athletes. Heavy training elevates IDO via inflammation. Some authors speculate this means tryptophan supplementation in athletes mostly produces kynurenines (some neurotoxic) rather than serotonin. Counterargument: the absolute amounts of tryptophan-derived kynurenine from a 1 g supplement are tiny vs endogenous flux; clinical depression/sleep benefit from supplementation in active populations has been observed. Don't lose sleep over the kynurenine path at 1 g/day. If hs-CRP comes back high, address inflammation directly — don't just stop the tryptophan.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: STRONG-CANDIDATE / HIGH confidence. Pharmacologically more relevant than glycine for Dylan's late-chronotype migration; A-tier evidence at 1 g+ doses; clean side effect profile; cheap; daily-safe; no tolerance. Replaces V4 glycine in V5 stack. Would shift to PRIMARY-PICK if June 2026 bloodwork shows specific deficits (low ferritin/B6) that would otherwise blunt response, and once 4-8 week trial confirms subjective sleep improvement. Would shift to OPTIONAL-ADD (away from STRONG) if 4-8 week trial shows no measurable improvement — at which point reassess as kynurenine-shunt-limited and consider addressing inflammation first.
▸ Open questions / gaps Open
  1. Does 4-8 week subchronic dosing in Dylan's profile actually shift sleep onset? Single best test: trial it. Bedtime sleep diary for 14 days baseline → switch glycine → tryptophan → re-measure 14-28 days.
  2. What's Dylan's baseline kynurenine:tryptophan ratio? Not standard bloodwork, but ZRT or specialty panels offer it. Worth ordering if cheap.
  3. 5-HTTLPR genotype — S/L/L vs S/S/L. Determines magnitude of expected response. June 2026 23andMe answer.
  4. MTHFR status — affects BH4 regeneration → TPH cofactor. June 2026 23andMe answer.
  5. Is there real WASO benefit at 1 g, or is this just SOL improvement that looks like WASO? Wearable sleep tracker (Dylan has Colmi R06) can give partial answer; PSG would be definitive but excessive for n=1.
  6. Can dose drop to 500 mg over time? Unknown — most lit uses 1 g+. Could trial down-titration after 8-12 weeks if response is robust.
▸ Sources (full, with our context)
Back to compact view